Ember Therapeutics, Inc.

Equities

EMBT

US29082W1099

Market Closed - OTC Markets Other stock markets 10:02:31 2023-09-20 am EDT			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2019	Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI
2018	Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI

Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..

August 15, 2018

Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc. (OTCPK:EMBT) on August 16, 2018. The OP-1 product family and related assets includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft for use in orthopaedic bone applications. The transaction is subject to financing and is expected to close in late Q3 or Q4 of this year.

Latest news about Ember Therapeutics, Inc.

Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..	19-08-15	CI
Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..	18-08-15	CI
Ember Therapeutics, Inc. acquired the assets of of Dermasilk Brands, Inc. from Midwood Distributors, Inc. for $1.3 million.	16-09-07	CI
Knight Therapeutics Inc. and Ember Therapeutics, Inc. Expand Distribution Partnership	16-07-06	CI
Ember Therapeutics, Inc. entered into a definitive agreement to acquire the assets of Migralex, Inc. for $0.87 million.	16-03-20	CI
Ember Therapeutics, Inc. acquired ICX-RHY/Vavelta from Intercytex Limited for $1.1 million.	16-03-15	CI
American Home Alliance Corp will Change its Ticker to EMBT from AHLL	16-02-24	CI
AMERICAN HOME ALLIANCE CORP will Change its Name to Ember Therapeutics, Inc	16-02-24	CI
Ember Therapeutics, Inc. acquired American Home Alliance Corp. in a reverse merger transaction.	16-02-02	CI
Ember Therapeutics, Inc. Announces Initial Positive Results from a Phase 2 Trial of BMP-7	15-10-19	CI
Mariel Therapeutics, Inc. acquired Ember Therapeutics, Inc. from Third Rock Ventures II, L.P. of Third Rock Ventures II, L.P. and others for $6 million.	15-03-11	CI
Ember Therapeutics, Inc. acquired Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation.	14-12-30	CI
Ember Therapeutics, Inc. Announces Publication of Key Preclinical Data Demonstrating Inhibition of Transient Receptor Potential Vanilloid	12-09-27	CI
Ember Therapeutics, Inc. Announces Management Appointments	12-05-29	CI
Ember Therapeutics, Inc. Closes License Deal with Joslin Diabetes Center	12-03-31	CI

Chart Ember Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company